Marshall Wace LLP Invests $736,000 in Kewaunee Scientific Co. (NASDAQ:KEQU)

Marshall Wace LLP bought a new position in Kewaunee Scientific Co. (NASDAQ:KEQU - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 11,902 shares of the technology company's stock, valued at approximately $736,000. Marshall Wace LLP owned approximately 0.41% of Kewaunee Scientific as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the business. JPMorgan Chase & Co. grew its holdings in shares of Kewaunee Scientific by 18,000.0% during the third quarter. JPMorgan Chase & Co. now owns 905 shares of the technology company's stock valued at $30,000 after buying an additional 900 shares during the last quarter. IFP Advisors Inc purchased a new stake in shares of Kewaunee Scientific in the fourth quarter worth approximately $36,000. Morgan Dempsey Capital Management LLC bought a new position in shares of Kewaunee Scientific in the fourth quarter valued at approximately $106,000. Barclays PLC purchased a new position in shares of Kewaunee Scientific during the third quarter valued at approximately $121,000. Finally, Wedbush Securities Inc. bought a new stake in Kewaunee Scientific during the fourth quarter worth $262,000. Institutional investors and hedge funds own 32.69% of the company's stock.

Insider Activity at Kewaunee Scientific

In other Kewaunee Scientific news, CEO Thomas David Hull III sold 1,844 shares of the business's stock in a transaction on Monday, April 14th. The stock was sold at an average price of $32.44, for a total value of $59,819.36. Following the sale, the chief executive officer now directly owns 36,072 shares in the company, valued at $1,170,175.68. The trade was a 4.86 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Donald T. Gardner III sold 3,000 shares of the company's stock in a transaction on Wednesday, March 26th. The shares were sold at an average price of $40.01, for a total value of $120,030.00. Following the transaction, the chief financial officer now directly owns 18,358 shares in the company, valued at $734,503.58. This represents a 14.05 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 11,057 shares of company stock worth $440,326. 14.20% of the stock is owned by company insiders.

Kewaunee Scientific Stock Down 4.9 %

Kewaunee Scientific stock traded down $1.60 during midday trading on Tuesday, hitting $30.95. 17,489 shares of the stock were exchanged, compared to its average volume of 24,344. The company has a quick ratio of 2.13, a current ratio of 2.64 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $88.36 million, a price-to-earnings ratio of 4.90 and a beta of 0.47. Kewaunee Scientific Co. has a 52-week low of $30.33 and a 52-week high of $71.33. The business's 50-day moving average price is $40.41 and its 200-day moving average price is $47.51.

Kewaunee Scientific (NASDAQ:KEQU - Get Free Report) last issued its quarterly earnings results on Wednesday, March 12th. The technology company reported $1.09 EPS for the quarter. Kewaunee Scientific had a return on equity of 25.83% and a net margin of 9.39%. The business had revenue of $67.17 million for the quarter.

Analyst Upgrades and Downgrades

Separately, StockNews.com cut Kewaunee Scientific from a "buy" rating to a "hold" rating in a research note on Friday, March 14th.

Kewaunee Scientific Company Profile

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. The company operates through two segments, Domestic and International. Its products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks.